| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Sameet Kanade CPA, MBA CEO | CNSX Exchange | CA85832P2089 ISIN |
| Canada Country | - Employees | - Last Dividend | 12 May 2026 Last Split | - IPO Date |
Steep Hill Inc., initially established in 2008 as Cannabis Clonal Corporation, underwent a significant rebranding in February 2022 when it adopted its current name. This rebranding marked a notable transition in its business focus. Historically, Steep Hill Inc. played an active role in the cannabis industry within Canada, operating primarily as a cannabis science company. However, as of the last update, Steep Hill Inc. does not engage in significant operations. The company, which has its foundations deeply rooted in the cannabis sector, attempted to carve a niche for itself by leveraging science and research to stand out in a rapidly evolving market. Despite its innovative approach and contributions to the cannabis science sphere, Steep Hill Inc. has pivoted away from its previous operational model. Situated in Toronto, Canada, the company embodies the dynamic and changing nature of the cannabis industry, highlighting the challenges and shifts companies may undergo in adapting to market demands and regulatory landscapes.
While Steep Hill Inc. has transitioned away from active operations in the cannabis science field, its historical contribution to the industry can be encapsilated through its past offerings. Details on its specific products and services during its operational phase are limited, reflecting the company's shift away from the cannabis sector. However, implied by its previous designation as a cannabis science company, Steep Hill Inc.'s offerings likely encompassed a range of scientific and analytical services tailored to the cannabis industry. These services may have included, but were not limited to:
Despite its current status, Steep Hill Inc.'s previous operations potentially played a role in supporting and advancing the cannabis industry's scientific and quality standards in Canada.